Treatmenttype 2 diabetes
ManufacturerTongmeng (Lao) Pharmaceutical & Food Co., Ltd.（TLPH）
Brand name: Enflon.
Generic name: Empaglifozin.
Dosage form: Tablet
Enpagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor; suitable for:
- As an aid to diet and exercise to improve blood sugar control in adults with type 2 diabetes.
- Reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular diseases.
- Restrictions on use: Not applicable to the treatment of patients with type 1 diabetes or diabetic ketoacidosis.
Dose and administration method
- Method of administration
- Recommended dosage of empagliflozin: 10mg once a day, taken in the morning, with or without food.
- The dose can be increased to 25mg once a day.
- Before taking empagliflozin, renal function needs to be assessed, and the glomerular filtration rate eGFR is estimated to be lower than Patients with 45ml/min/1.73m2 should not take empagliflozin. If the eGFR value of glomerular filtration rate is estimated to be less than 45ml/min/1.73m2 during taking, you should Stop the drug.
- Dosage specifications
- Tablets, 10mg, 25mg.
- Contraindications: patients with a history of severe hypersensitivity to Enpagliflozin should not take it; severe renal impairment, renal Patients with terminal illness or dialysis should not take it.
Warnings and Precautions
- Hypotension: In patients with renal impairment, elderly patients, patients with low systolic blood pressure, and taking
In diuretic patients, before starting to take empagliflozin, renal volume contraction should be evaluated and corrected
state. During the administration period, closely monitor the signs and symptoms of hypotension.
- Ketoacidosis: Regardless of the level of blood sugar, patients with ketoacidosis must evaluate before taking it.
Assess the signs and symptoms of metabolic ketoacidosis in patients. If ketoacidosis is suspected, stop the drug in time and suffer
Reassess the patient and start treatment in time. Before taking empagliflozin, consider the triggering factor of ketoacidosis and take
Enpagliflozin patients may need to temporarily stop if they are monitored for possible ketoacidosis during treatment
(Please read this notice carefully and take the medicine according to this notice or under the guidance of a doctor)
- Acute kidney injury and renal impairment: consider temporary interruption to reduce oral intake or fluid loss. Such as
If acute kidney injury occurs, stop and treat immediately. Monitor renal function during treatment.
- Uremia and pyelonephritis: evaluate the patient’s signs and symptoms of urinary tract infection, if applicable,
- Hypoglycemia: Consider reducing the dose of insulin secretagogue or insulin to reduce taking Englita
The risk of net hour hypoglycemia.
- Fungal infections of the genital tract: proper monitoring and treatment.
- Increase in low-density lipoprotein cholesterol (LDL-C): proper monitoring and treatment.
The most common (≥5% incidence) adverse reactions associated with empagliflozin are urinary tract infections and female reproduction
Organ fungal infection.
Store at 25°C (77°F), and allow an offset of 15°-30°C (59°-86°F).